Built using insights from more than 100 million property claims, the Property Lab recreates realistic home damage scenarios to help claim adjusters build the expertise needed to guide customers through the repair process
Key Takeaways
The Property Lab was built using insights from more than 100 million property claims, helping recreate many of the damage scenarios customers experience most often. Two full-size, two-story homes with a basement bring real-world property damage scenarios to life, from burst pipes and roof leaks to hail-damaged roofing materials and lightning-damaged equipment. Interactive technology and hands-on learning environments allow claim adjusters to explore how damage occurs, spreads through a home and is ultimately repaired, supporting more accurate assessments and clearer explanations for customers about what needs to be repaired and why. , /PRNewswire/ -- The Property Lab at Allstate Claims University is a full-scale residential training facility, featuring two complete, two-story homes where Allstate claim adjusters inspect staged home damage before helping customers navigate real property damage situations. The Property Lab is one of two hands-on training environments inside Allstate Claims University, the company's 33,000-square-foot claims training center in Dallas, Texas, which opened in August 2026. Built using insights from more than 100 million property claims, the Property Lab recreates the residential damage scenarios customers experience most often.
Allstate Claims University Property Lab
Allstate Claims University Property Lab The Property Lab is part of Allstate's broader investment in claim adjusters, equipping them with practical knowledge that helps them guide customers through the repair and recovery process.
Mike Fiato, executive vice president and chief claims officer at Allstate:
"Customers trust Allstate during some of the most stressful moments they face as homeowners. The Property Lab gives our teams hands-on experience with real-world damage scenarios, helping them provide informed guidance and support when it matters most."
Frequently Asked Questions
What is the Property Lab at Allstate Claims University?
The Property Lab is a hands-on training environment that allows claim adjusters to experience realistic residential damage scenarios in full-scale homes. Claim adjusters can inspect damage, examine what may be happening behind walls, ceilings and floors and gain firsthand experience with the situations they may encounter while helping customers recover. The homes feature a range of construction materials and finishes, from standard-grade components to higher-end materials, helping claim adjusters gain experience with the variety of homes, materials and repair considerations before directly supporting customers.
How does Allstate train property claim adjusters?
The Property Lab prepares claim adjusters for real-world home damage scenarios by:
Inspecting visible damage on the exterior and interior of full-size, two-story homes. Using cutaway wall sections to trace how damage travels through framing, insulation and plumbing. Engaging with interactive digital tools showing damage patterns and repair techniques. Practicing identifying hidden damage beyond the visible point of origin. Completing module-based training on roofing, water damage, cabinetry, plumbing, electrical and sump-pump systems. What kinds of damage are featured in the Property Lab?
The Property Lab recreates a variety of situations commonly encountered in residential property claims, including:
Water and plumbing damage, including burst pipes, water intrusion, leaking appliances and drain backups Roof, hail and storm-related exterior damage, including roof and skylight leaks Fire, smoke and heat-related damage, including smoke and grease-fire damage and fire-related siding damage Lightning-related damage to home systems and equipment, including HVAC units and electrical components What equipment and technology does the Property Lab use to train claim adjusters?
The Property Lab combines physical damage demonstrations with digital learning tools that provide immediate information about damage patterns, repair techniques and restoration considerations. Interactive technology throughout the homes allows claim adjusters to move beyond observation and explore how different types of damage develop, spread and are repaired.
The facility also includes industry-standard roofing, water damage, cabinetry, plumbing, electrical and sump-pump training modules, creating a learning experience that closely mirrors conditions encountered in residential claims.
What happens during an Allstate home insurance claim inspection?
When a homeowner files a property claim with Allstate, a claim adjuster assesses both visible and potential hidden damage, evaluates how the damage originated and spread through the home's structure, reviews applicable coverage and guides the homeowner through repair options and next steps. The Property Lab prepares claim adjusters for this process, particularly for cases where the visible damage is only part of the story.
About Allstate
The Allstate Corporation (NYSE: ALL) protects people from life's uncertainties with affordable, simple and connected protection for autos, homes, electronic devices and identities. Products are available through a broad distribution network including Allstate agents, independent agents, major retailers, online and at the workplace. Allstate has 216 million policies in force and is widely known for the slogan "You're in Good Hands with Allstate." For more information, visit www.allstate.com.
, /PRNewswire/ -- Ares Capital Corporation (Nasdaq: ARCC) announced that it has priced an underwritten public offering of $750 million in aggregate principal amount of 6.250% notes due 2033. The notes will mature on September 15, 2033 and may be redeemed in whole or in part at Ares Capital's option at any time at par plus a "make-whole" premium, if applicable.
BofA Securities, Inc., J.P. Morgan Securities LLC, RBC Capital Markets, LLC, SMBC Nikko Securities America, Inc., Wells Fargo Securities, LLC, Barclays Capital Inc., CIBC World Markets Corp., Mizuho Securities USA LLC, MUFG Securities Americas Inc., TD Securities (USA) LLC, Truist Securities, Inc. and U.S. Bancorp Investments, Inc. are acting as joint book-running managers for this offering. BNP Paribas Securities Corp., Capital One Securities, Inc., HSBC Securities (USA) Inc., Morgan Stanley & Co. LLC, Regions Securities LLC, SG Americas Securities, LLC, BNY Mellon Capital Markets, LLC, Credit Agricole Securities (USA) Inc., Goldman Sachs & Co. LLC, ICBC Standard Bank Plc and Natixis Securities Americas LLC are acting as joint lead managers for this offering. Ares Management Capital Markets LLC, Deutsche Bank Securities Inc., ING Financial Markets LLC, R. Seelaus & Co., LLC, Academy Securities, Inc., Citigroup Global Markets Inc., Keefe, Bruyette & Woods, Inc., Loop Capital Markets LLC, Samuel A. Ramirez & Company, Inc. and Siebert Williams Shank & Co., LLC are acting as co-managers for this offering. The offering is expected to close on September 15, 2026, subject to customary closing conditions.
Ares Capital expects to use the net proceeds of this offering to repay certain outstanding indebtedness under its debt facilities. Ares Capital may reborrow under its debt facilities for general corporate purposes, which include investing in portfolio companies in accordance with its investment objective.
Investors are advised to carefully consider the investment objective, risks, charges and expenses of Ares Capital before investing. The pricing term sheet dated September 8, 2026, the preliminary prospectus supplement dated September 8, 2026, and the accompanying prospectus dated May 1, 2024, each of which have been filed with the Securities and Exchange Commission, contain this and other information about Ares Capital and should be read carefully before investing.
The information in the pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release is not complete and may be changed. The pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release are not offers to sell any securities of Ares Capital and are not soliciting an offer to buy such securities in any jurisdiction where such offer and sale is not permitted.
The offering may be made only by means of a preliminary prospectus supplement and an accompanying prospectus. Copies of the preliminary prospectus supplement (and accompanying prospectus) may be obtained from
Prospectus Department, or by calling 1-800-294-1322, or email [email protected]; J.P. Morgan Securities LLC, 270 Park Avenue, New York, NY 10017, Attn: Investment Grade Syndicate Desk, 212-834-4533; RBC Capital Markets, LLC, Brookfield Place, 200 Vesey Street, 8th Floor, New York, NY 10281, by toll-free telephone at 1-866-375-6829 or email [email protected]; SMBC Nikko Securities America, Inc. at 277 Park Avenue, New York, New York 10172, Attn: [email protected]; or Wells Fargo Securities, LLC at 1-800-645-3751.
ABOUT ARES CAPITAL CORPORATION
Founded in 2004, Ares Capital is a leading specialty finance company focused on providing direct loans and other investments in private middle market companies in the United States. Ares Capital's objective is to source and invest in high-quality borrowers that need capital to achieve their business goals, which oftentimes can lead to economic growth and employment. Ares Capital believes its loans and other investments in these companies can help generate attractive levels of current income and potential capital appreciation for investors. Ares Capital, through its investment manager, utilizes its extensive, direct origination capabilities and incumbent borrower relationships to source and underwrite predominantly senior secured loans but also subordinated debt and equity investments. Ares Capital has elected to be regulated as a business development company ("BDC") and was the largest publicly traded BDC by market capitalization as of June 30, 2026. Ares Capital is externally managed by a subsidiary of Ares Management Corporation (NYSE: ARES), a publicly traded, leading global alternative investment manager.
FORWARD-LOOKING STATEMENTS
Statements included herein may constitute "forward-looking statements," which relate to future events or Ares Capital's future performance or financial condition. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results and conditions may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Ares Capital's filings with the Securities and Exchange Commission. Ares Capital undertakes no duty to update any forward-looking statements made herein.
INVESTOR RELATIONS CONTACTS
Ares Capital Corporation
John Stilmar or Carl Drake
888-818-5298
[email protected]
In the latest trading session, Ares Capital (ARCC - Free Report) closed at $19.70, marking a -1.7% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.58%. Elsewhere, the Dow saw a downswing of 1.18%, while the tech-heavy Nasdaq depreciated by 0.32%.
The stock of private equity firm has risen by 0.3% in the past month, leading the Finance sector's gain of 0.23% and the S&P 500's loss of 0.36%.
Market participants will be closely following the financial results of Ares Capital in its upcoming release. In that report, analysts expect Ares Capital to post earnings of $0.48 per share. This would mark a year-over-year decline of 4%. Simultaneously, our latest consensus estimate expects the revenue to be $780.31 million, showing a 0.22% drop compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $1.91 per share and a revenue of $3.1 billion, representing changes of -4.98% and +1.7%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Ares Capital. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Ares Capital currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Ares Capital currently has a Forward P/E ratio of 10.51. This denotes a premium relative to the industry average Forward P/E of 8.38.
The Financial - SBIC & Commercial Industry industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ARCC in the coming trading sessions, be sure to utilize Zacks.com.
Warner Bros. Discovery (WBD - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this operator of cable TV channels such as TLC and Animal Planet have returned +5.1% over the past month versus the Zacks S&P 500 composite's -0.4% change. The Zacks Broadcast Radio and Television industry, to which Warner Bros. Discovery belongs, has gained 4.3% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Warner Bros. Discovery is expected to post earnings of $0.02 per share, indicating a change of +133.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +271.4% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of -$1.11 points to a change of -482.8% from the prior year. Over the last 30 days, this estimate has changed +3.9%.
For the next fiscal year, the consensus earnings estimate of $0.17 indicates a change of +114.6% from what Warner Bros. Discovery is expected to report a year ago. Over the past month, the estimate has changed -440%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Warner Bros. Discovery.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Warner Bros. Discovery, the consensus sales estimate for the current quarter of $8.84 billion indicates a year-over-year change of -2.3%. For the current and next fiscal years, $36.26 billion and $37.58 billion estimates indicate -2.8% and +3.6% changes, respectively.
Last Reported Results and Surprise HistoryWarner Bros. Discovery reported revenues of $8.72 billion in the last reported quarter, representing a year-over-year change of -11.2%. EPS of $0.06 for the same period compares with $0.63 a year ago.
Compared to the Zacks Consensus Estimate of $9.29 billion, the reported revenues represent a surprise of -6.19%. The EPS surprise was +146.15%.
Over the last four quarters, the company surpassed EPS estimates just once. The company topped consensus revenue estimates just once over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Warner Bros. Discovery is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Warner Bros. Discovery. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Key Takeaways Lilly's neuroscience revenues rose 32% to $811 million in the first half of 2026.Lilly is expanding its neuroscience pipeline across Alzheimer's, sleep disorders, pain and neurodegeneration.Acquisitions are adding promising neuroscience assets, including BPL-003 for treatment-resistant depression. Eli Lilly and Company (LLY - Free Report) boasts a wide range of products across cardiometabolic health, neuroscience, oncology and immunology. Cardiometabolic Health is Lilly’s largest therapeutic area by a wide margin, particularly with the success of its tirzepatide medicines, Mounjaro and Zepbound. Its cardiometabolic products accounted for approximately 80% of Lilly’s total revenues in the first half of 2026.
However, Lilly is gradually building a more diversified portfolio by expanding in oncology, immunology and neuroscience. Lilly has also embarked on an aggressive M&A spree in the past couple of years, acquiring biotech companies across oncology, neuroscience, cardiovascular disease, gene editing, inflammation, cell therapy and vaccines to diversify its long-term growth drivers beyond GLP-1 therapies.
In this article, we will discuss Lilly’s position in the neuroscience space and how it is expanding its presence in this area.
Neuroscience Still Small but Has Significant Growth PotentialNeuroscience currently represents only a small portion of Lilly's sales, around 2%. In the first six months of 2026, neuroscience revenues increased around 32% to $811 million. The portfolio currently has two major marketed products — Emgality, an anti-CGRP monoclonal antibody for migraine prevention and Kisunla, an anti-amyloid beta antibody for early symptomatic Alzheimer's disease. Of these, Kisunla is seeing rapid year-over-year sales growth.
The relatively small contribution means neuroscience is not yet an important earnings driver for Lilly, but it also means the upside could be substantial if its neuroscience pipeline succeeds.
Lilly Building a Broader Neuroscience Pipeline Through M&ALilly has built a considerably deeper neuroscience pipeline. Key candidates are remternetug, a next-generation anti-amyloid antibody being developed for Alzheimer's disease in phase III, cleminorexton, an orexin receptor 2 agonist in phase II/III for hypersomnia and a GBA1 gene therapy for Parkinson's disease in phase II.
Acquisitions have played an important role in building Lilly’s neuroscience franchise. In July, Lilly agreed to acquire AtaiBeckley (ATAI - Free Report) , which is advancing a pipeline of rapid-acting neuroplastogens for treatment-resistant depression (TRD) and other mental health conditions. ATAI’s lead asset, BPL-003, an intranasal formulation of mebufotenin benzoate, is being developed as a potential treatment for people living with TRD. The candidate has shown encouraging mid-stage data in TRD.
The acquisition of Centessa added cleminorexton to the pipeline. In previous years, acquisitions like Prevail Therapeutics and Disarm Therapeutics added candidates to treat neurological diseases.
Overall, Lilly’s neuroscience pipeline now spans Alzheimer's, sleep disorders, pain, schizophrenia, neurodegeneration and other neurological conditions.
ConclusionLilly’s neuroscience business is still small, but its strong growth, expanding pipeline and M&A-driven additions could make it an increasingly important long-term growth driver. The success of key candidates could help Lilly diversify its revenue base and reduce its reliance on cardiometabolic therapies.
Competition to LLY’s Neuroscience ProductsKisunla’s single biggest competitor is Eisai/Biogen’s (BIIB - Free Report) Leqembi, both being amyloid-targeting treatments. Other companies are also developing next-generation Alzheimer's therapies, including Roche/Genentech and several biotech companies.
Emgality (galcanezumab) competes in the highly competitive CGRP migraine market, which includes Teva’s Ajovy, Amgen/Novartis’ Aimovig, Pfizer’s (PFE - Free Report) Nurtec ODT and AbbVie’s Qulipta.
LLY’s Stock Price, Valuation and EstimatesLilly’s stock has risen 6.9% so far this year compared with the industry’s increase of 14.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, Lilly’s stock is expensive. Going by the price/earnings ratio, the company’s shares currently trade at 26.85 forward earnings, higher than 18.70 for the industry. However, the stock is trading below its 5-year mean of 34.57.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 has risen from $35.56 to $35.93 per share over the past 60 days, while that for 2027 has risen from $44.58 to $45.93 per share over the same timeframe.
Image Source: Zacks Investment Research
Lilly has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Recognition reflects Gen's commitment to turning bold ideas into meaningful innovation
, /PRNewswire/ -- Gen (NASDAQ: GEN), the global leader powering digital freedom behind its trusted brands Norton, Avast, LifeLock and MoneyLion, has been named one of Fast Company's Best Workplaces for Innovators 2026.
The recognition reflects Gen's ability to turn emerging customer needs and challenges into products and experiences that help people protect what matters, manage their finances and move through their digital and financial lives with greater confidence and control.
At Gen, innovation starts with a simple question: What problem are people actually experiencing, and how can we help solve it?
When researchers and product teams identify a threat, a gap, a pain point, they have the freedom to act. Teams form, organize around the opportunity and build the customer case, not just the business case. With access to the tools, data and cross-functional support they need, squads can move ideas from insight to impact.
"AI is accelerating innovation, but speed only matters when it creates something useful for people," said Vincent Pilette, CEO of Gen. "Innovation at scale requires empowered teams, clear ownership, the right tools and data, and a deep understanding of customer needs. We have made meaningful progress, and we still have much more to learn."
Gen's Safety Lab and AI Foundry bring this approach to life. Rooted in safety and transparency, they serve as both a trust layer and an incubator for the company's latest AI innovations, helping business teams develop AI-native solutions grounded in real customer needs.
As AI becomes part of everyday life, Norton Genie becomes our super agent providing cyber safety recommendations and actions. Norton Neo brings intelligence directly into the browser while making security and privacy built in from the start. For parents managing emails, calendars, school platforms and messaging across a dozen services, Norton Family Assistant brings those pieces together, surfacing what needs attention and reducing the coordination burden on families. And as people increasingly rely on agentic AI, Gen's Agent Trust Hub helps assess those agents for malicious instructions and unsafe permissions before they are put to use.
These innovations did not begin in a strategic planning cycle. They began when employees saw a need and had the freedom to pursue a solution.
The same model powers innovation across Gen. Companywide hackathons and an always-on ideas portal invite Genies across all functions to develop new products, automate work, and improve how Gen serves customers. Cross-functional teams then help turn the most promising ideas into experiences that can make a difference for millions of people.
Fast Company's recognition highlights the culture Gen embodies, where innovation comes to life by solving problems people face. Whether Gen employees are developing new ways to help people stay safer online, manage their finances or finding a better way to serve customers, the goal is the same: create useful innovation that helps people navigate the risks, decisions and opportunities shaping their digital and financial lives.
About Gen
Gen (NASDAQ: GEN) is a global company dedicated to powering Digital Freedom through its trusted consumer brands including Norton, Avast, LifeLock, MoneyLion and more. The Gen family of consumer brands is rooted in providing financial empowerment and cyber safety for the first digital generations. Today, Gen empowers people to live their digital lives safely, privately and confidently for generations to come. Gen brings award-winning products and services in cybersecurity, online privacy, identity protection and financial wellness to nearly 500 million users in more than 150 countries. Learn more at GenDigital.com.
Investors interested in Business Services stocks should always be looking to find the best-performing companies in the group. Gen Digital (GEN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Gen Digital is a member of the Business Services sector. This group includes 248 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Gen Digital is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for GEN's full-year earnings has moved 1.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, GEN has gained about 12.7% so far this year. At the same time, Business Services stocks have lost an average of 9.2%. This means that Gen Digital is performing better than its sector in terms of year-to-date returns.
Ingram Micro (INGM - Free Report) is another Business Services stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 35.2%.
The consensus estimate for Ingram Micro's current year EPS has increased 3.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Gen Digital belongs to the Technology Services industry, a group that includes 122 individual stocks and currently sits at #162 in the Zacks Industry Rank. On average, stocks in this group have lost 10.5% this year, meaning that GEN is performing better in terms of year-to-date returns. Ingram Micro is also part of the same industry.
Gen Digital and Ingram Micro could continue their solid performance, so investors interested in Business Services stocks should continue to pay close attention to these stocks.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer. "David Bailey doesn't just know STAAR, he helped change the trajectory of the entir.
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at the following financial conference. The presentation will be webcast live via the Investor Relations section of Align's website at ht.
Align Technology, Inc. (NASDAQ:ALGN – Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 2,293 call options on the stock. This represents an increase of 72% compared to the typical daily volume of 1,334 call options.
Analysts Set New Price Targets A number of analysts recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Align Technology in a report on Thursday, July 30th. UBS Group reiterated a “neutral” rating and set a $189.00 target price on shares of Align Technology in a research note on Thursday, July 23rd. BMO Capital Markets started coverage on shares of Align Technology in a report on Wednesday, July 8th. They issued an “outperform” rating and a $209.00 price target on the stock. Weiss Ratings upgraded shares of Align Technology from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday. Finally, Zacks Research lowered shares of Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $206.36.
Check Out Our Latest Stock Report on Align Technology
Shares of NASDAQ ALGN opened at $153.49 on Wednesday. The stock has a fifty day simple moving average of $170.91 and a two-hundred day simple moving average of $173.44. Align Technology has a 1-year low of $122.00 and a 1-year high of $200.43. The firm has a market cap of $10.99 billion, a price-to-earnings ratio of 26.69, a price-to-earnings-growth ratio of 1.69 and a beta of 1.65. Align Technology (NASDAQ:ALGN – Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.02. Align Technology had a return on equity of 15.86% and a net margin of 9.99%.The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period last year, the business posted $2.49 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. Analysts forecast that Align Technology will post 9.38 EPS for the current year.
Institutional Investors Weigh In On Align Technology Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its holdings in Align Technology by 5.9% during the second quarter. NewEdge Advisors LLC now owns 2,826 shares of the medical equipment provider’s stock valued at $477,000 after purchasing an additional 157 shares during the last quarter. Squarepoint Ops LLC boosted its position in Align Technology by 101.1% during the second quarter. Squarepoint Ops LLC now owns 3,567 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 1,793 shares during the period. Baird Financial Group Inc. increased its stake in shares of Align Technology by 11.2% in the second quarter. Baird Financial Group Inc. now owns 128,428 shares of the medical equipment provider’s stock worth $21,661,000 after purchasing an additional 12,945 shares in the last quarter. Beacon Investment Advisory Services Inc. increased its stake in shares of Align Technology by 14.7% in the second quarter. Beacon Investment Advisory Services Inc. now owns 3,081 shares of the medical equipment provider’s stock worth $520,000 after purchasing an additional 394 shares in the last quarter. Finally, Allworth Financial LP raised its position in shares of Align Technology by 3.1% in the second quarter. Allworth Financial LP now owns 3,393 shares of the medical equipment provider’s stock valued at $572,000 after purchasing an additional 101 shares during the period. 88.43% of the stock is currently owned by institutional investors.
About Align Technology (Get Free Report)
Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.
The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.
Further Reading Five stocks we like better than Align Technology Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.
In the latest close session, Riot Platforms, Inc. (RIOT - Free Report) was up +1.63% at $22.16. The stock's performance was ahead of the S&P 500's daily loss of 0.58%. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%.
Shares of the company have appreciated by 12.37% over the course of the past month, outperforming the Finance sector's gain of 0.23%, and the S&P 500's loss of 0.36%.
The investment community will be closely monitoring the performance of Riot Platforms, Inc. in its forthcoming earnings report. The company is expected to report EPS of -$0.33, down 226.92% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $162.75 million, indicating a 9.7% downward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$2.71 per share and revenue of $670.27 million, which would represent changes of -38.97% and +3.53%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Riot Platforms, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 16.54% lower within the past month. Riot Platforms, Inc. is currently a Zacks Rank #4 (Sell).
The Financial - Miscellaneous Services industry is part of the Finance sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
JD.com, Inc. (JD - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this company have returned -15.6%, compared to the Zacks S&P 500 composite's -0.4% change. During this period, the Zacks Internet - Commerce industry, which JD.com falls in, has lost 6.2%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
JD.com is expected to post earnings of $0.96 per share for the current quarter, representing a year-over-year change of +84.6%. Over the last 30 days, the Zacks Consensus Estimate has changed -10.2%.
For the current fiscal year, the consensus earnings estimate of $3.19 points to a change of +25.1% from the prior year. Over the last 30 days, this estimate has changed +1.7%.
For the next fiscal year, the consensus earnings estimate of $3.73 indicates a change of +17% from what JD.com is expected to report a year ago. Over the past month, the estimate has changed +0.6%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for JD.com.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For JD.com, the consensus sales estimate for the current quarter of $45.85 billion indicates a year-over-year change of +9.1%. For the current and next fiscal years, $202.28 billion and $212.68 billion estimates indicate +10.1% and +5.1% changes, respectively.
Last Reported Results and Surprise HistoryJD.com reported revenues of $51.05 billion in the last reported quarter, representing a year-over-year change of +2.5%. EPS of $0.93 for the same period compares with $0.69 a year ago.
Compared to the Zacks Consensus Estimate of $51.55 billion, the reported revenues represent a surprise of -0.96%. The EPS surprise was +8.14%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates two times over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
JD.com is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about JD.com. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about XPeng Inc. Sponsored ADR (XPEV - Free Report) .
XPeng currently has an average brokerage recommendation (ABR) of 1.82, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 19 brokerage firms. An ABR of 1.82 approximates between Strong Buy and Buy.
Of the 19 recommendations that derive the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 63.2% and 10.5% of all recommendations.
Brokerage Recommendation Trends for XPEV
Check price target & stock forecast for XPeng here>>>
The ABR suggests buying XPeng, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Should You Invest in XPEV?In terms of earnings estimate revisions for XPeng, the Zacks Consensus Estimate for the current year has declined 70.1% over the past month to -$0.67.
Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for XPeng. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, it could be wise to take the Buy-equivalent ABR for XPeng with a grain of salt.
For years, the humanoid robotics race has been about proving the technology works. This week, the conversation shifted to something arguably more important: whether companies can manufacture these machines at scale.
Announcements from Tesla Inc (NASDAQ:TSLA) and XPeng Inc. (NYSE:XPEV) suggest the industry’s next battleground is no longer intelligence—it’s production.
Tesla Optimus ProductionTesla has reportedly taken a significant step toward scaling its Optimus humanoid robot. According to a report by Chinese outlet Jiemian News, citing supply-chain sources, the company has placed its first large-scale component order covering roughly 5,000 Optimus robots, marking the program’s first procurement in the thousands. Tesla has not publicly confirmed the report.
The reported order comes as suppliers prepare for production audits and higher manufacturing volumes, signaling that the focus is moving beyond prototype development and toward repeatable factory output. It also aligns with Tesla’s earlier guidance that first-generation Optimus production lines are being installed in Fremont ahead of volume production.
While Tesla has previously showcased Optimus performing factory tasks, large-scale manufacturing has remained the bigger challenge. If the supply-chain reports prove accurate, the company’s priorities are beginning to shift from engineering demonstrations to execution.
Read Next
XPENG Robot FactoryXPENG made an equally notable announcement from China.
CEO He Xiaopeng said the company has launched what it describes as the world’s first automated production line for advanced general-purpose humanoid robots, with robots assembling other robots autonomously. Calling the milestone “uncharted territory,” He said the production line means humanoid robots are now ready to “scale up and step into the real world.”
The announcement builds on XPENG’s previously disclosed ambition to begin large-scale production of its IRON humanoid robot by the end of 2026 and eventually expand commercial deployments beyond factories.
Unlike earlier product unveilings that emphasized robot capabilities, XPENG’s latest update puts manufacturing at the center of its strategy—suggesting production capacity is becoming as important as artificial intelligence itself.
What Investors Should WatchTesla’s reported production order and XPENG’s automated robot factory point to the same emerging trend: the humanoid robotics industry is entering its manufacturing phase.
That does not mean mass adoption is imminent. Companies still need to prove these robots can perform useful work reliably and economically. But if the race is indeed shifting from prototypes to production, investors may need to look beyond the robot makers themselves.
Component suppliers, precision manufacturers and industrial automation companies could become just as important as the firms building the humanoids, especially if large-scale production becomes the industry’s next competitive advantage.
Read Next
Image created using artificial intelligence via ChatGPT
Chinese companies rushed into electric cars a decade ago, and now they are expanding into humanoid robots as the EV market sees a slowdown amid intense competition.
While the commercial viability of humanoids has come under scrutiny, it hasn't dissuaded companies such as Xpeng from announcing robot production plans, at a time when China's EV sales are headed for their worst year since 2021.
It's part of a bid to reshape "capital valuation narratives," said Kevin Li, associate director at Counterpoint Research. He added that the automakers are also looking to boost the perception that they are tech companies, and establish a second growth curve.
Xpeng shares have tumbled more than 45% this year, making them the worst performer among major EV players. Shares of EV giant BYD are down more than 13% as sales have slumped.
Chinese automakers accounted for more than half of the nearly 20 car companies globally that have entered the humanoid robotics sector through in-house development, investment or incubation as of August, according to Counterpoint.
watch now
The venture arm of EV company Nio has also invested in several humanoid robotics startups such as LimX Dynamics and Acorn Robot, according to PitchBook data.
The business diversification comes as slowing growth and weakening profitability put pressure on China's EV makers. The average profit margin in China's vehicle manufacturing sector stood at 1.5% in the first half of 2026, according to China Association of Automobile Manufacturers data cited by Counterpoint.
Xiaomi, Li Auto and Geely are also among EV makers making moves into the robotics sector, although their strategies differ.
"Given the slowing growth and weakening profitability in the EV market—particularly domestically—it is a natural strategic move for EV companies to diversify into new applications such as robotics," said Jing Yang, director of Asia-Pacific corporate ratings at Fitch Ratings.
"This allows them to pursue alternative growth drivers, achieve economies of scale for shared advanced technologies, and potentially improve profitability over the medium term," she said.
Investors aren't buying the story yet.
Xpeng shares fell after it raised $900 million for its robotics business last month, the largest single round in China's "embodied" AI industry, according to the company. Embodied AI refers to hardware-connected artificial intelligence.
The raise valued the car company's robotics unit at more than $6.3 billion — on par with the $6.5 billion estimated value for Xpeng's EV business, according to Citi.
Advantages over Tesla?While there are similarities to how electric-car maker Tesla is developing its Optimus humanoid in the U.S., Elon Musk's company, the Chinese automakers' push into robotics have their own advantages, said Xiaoyi Lei, senior research analyst at Jefferies Hong Kong.
She pointed out that Chinese automakers can reuse a significant portion of their supply chain — Xpeng, for example, can use 85% of its motors, chips and smart driving software for humanoids. The robots can then be immediately deployed in the automakers' stores and factories, rather than having to wait for consumers to buy them, she added.
Xpeng said Tuesday it plans to begin mass production of its robots by the end of this year, starting in its own stores and business venues. Next year, the company plans to launch the robots to the broader market in China and overseas.
Automakers also know how to build things at scale, Lei said. Producing thousands of robots that are reliable and serviceable is what Chinese automakers already do every day, she added.
"Chinese players are the ones actually pushing it into daily use," Lei said, noting that in-house deployment makes it easier and cheaper for the automakers to collect data — which is critical for humanoid commercialization.
Xiaomi, a consumer electronics company that only launched its first electric car in 2024, started testing humanoid robots at its factory this year.
BYD can also deploy robots in its factories, Counterpoint's Li pointed out. But he said over the medium-to-long term, Geely and Xpeng could better capture the benefits of diversifying beyond cars, pointing to Xpeng's greater emphasis on its physical AI strategy.
Humanoid questionsWhether humanoid robots can generate demand beyond automakers' own operations remains an open-ended question. Lei said Jefferies has yet to see firm external orders from the automakers it covers or clear guidance on external customers and robotics revenue for next year.
Leading humanoid company Unitree saw its shares skyrocket as they debuted in Shanghai last month, but the stock declined for 12 of the 16 sessions since its listing. Founder Wang Xingxing has cautioned that commercialization could still take years, with the humanoid sector's 'ChatGPT' moment likely a decade away.
Reusing car technology for robots may not always be as straightforward as it sounds.
"I would say the real challenge is how they are going to make the algorithm and software stack that is used to be applied to the smart driving system also viable to the humanoid scenario, which is more difficult and more challenging," Lei said.
Affirm maintained strong double-digit growth in gross merchandise volume and active users in Q4, driven by robust BNPL adoption and rapid Affirm Card uptake. Affirm is benefiting from massive Affirm Card GMV growth, with the Visa debit card now representing 20% of total GMV. Rising inflation and geopolitical tensions have shifted rate expectations, making near-term Fed rate cuts unlikely and pressuring rate-sensitive fintech valuations.
Institutional Class shares of Columbia Select Mid Cap Growth Fund returned 26.69% for the period ending June 30, 2026. Contributors to relative performance Kioxia Holdings, Hut 8 and Sandisk. Detractors from relative performance Spotify, Cloudflare and Astera Labs.
Datasea (NASDAQ:DTSS – Get Free Report) and Fortinet (NASDAQ:FTNT – Get Free Report) are both technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Earnings & Valuation This table compares Datasea and Fortinet”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Datasea $40.70 million 0.17 -$2.13 million ($0.32) -2.06 Fortinet $6.80 billion 16.86 $1.85 billion $2.84 55.03 Fortinet has higher revenue and earnings than Datasea. Datasea is trading at a lower price-to-earnings ratio than Fortinet, indicating that it is currently the more affordable of the two stocks. Analyst Recommendations This is a summary of current ratings and recommmendations for Datasea and Fortinet, as reported by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Datasea 1 0 0 0 1.00 Fortinet 5 19 10 2 2.25 Fortinet has a consensus target price of $150.91, suggesting a potential downside of 3.44%. Given Fortinet’s stronger consensus rating and higher possible upside, analysts clearly believe Fortinet is more favorable than Datasea.
Profitability This table compares Datasea and Fortinet’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Datasea -4.80% -88.98% -37.33% Fortinet 28.17% 191.54% 21.35% Insider and Institutional Ownership 82.1% of Datasea shares are held by institutional investors. Comparatively, 83.7% of Fortinet shares are held by institutional investors. 50.6% of Datasea shares are held by insiders. Comparatively, 17.6% of Fortinet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk Datasea has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Fortinet has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.
Summary Fortinet beats Datasea on 14 of the 15 factors compared between the two stocks.
About Datasea (Get Free Report)
Datasea Inc., through its subsidiaries, provides technology and information systems in the People's Republic of China. The company provides smart city solutions and 5G messaging applications. It also offers its smart security solutions primarily to schools, tourist or scenic attractions, and public communities. In addition, the company provides intelligent acoustics products, which include ultrasonic air sterilizer, air purification and deodorization, and other products. The company was formerly known as Rose Rock, Inc. and changed its name to Datasea Inc. in October 2015. Datasea Inc. was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.
About Fortinet (Get Free Report)
Fortinet, Inc. provides cybersecurity and convergence of networking and security solutions worldwide. It offers secure networking solutions focus on the convergence of networking and security; network firewall solutions that consist of FortiGate data centers, hyperscale, and distributed firewalls, as well as encrypted applications; wireless LAN solutions; and secure connectivity solutions, including FortiSwitch secure ethernet switches, FortiAP wireless local area network access points, FortiExtender 5G connectivity gateways, and other products. The company also provides the Fortinet Unified SASE solutions that include firewall, SD-WAN, Secure web gateway, cloud access services broker, data loss prevention, zero trust network access, and cloud security, including web application firewalls, virtualized firewalls, and cloud-native firewalls. In addition, it offers security operations solutions comprising FortiAI generative AI assistant, FortiSIEM security information and event management, FortiSOAR security orchestration, automation and response, FortiEDR endpoint detection and response, FortiXDR extended detection and response, FortiMDR managed detection and response service, FortiNDR network detection and response, FortiRecon digital risk protection, FortiDeceptor deception technology, FortiGuard SoCaaS, FortiSandbox sandboxing, FortiGuard incident response, and other products. Further, the company offers FortiGuard security services consisting of FortiGuard application security, content security, device security, NOC/SOC security, and web security services; FortiCare technical support services; and training services to customers and channel partners, as well as operates a FortiGuard Lab, a cybersecurity threat intelligence and research organization. It serves enterprise, communication and security service providers, government organizations, and small and medium-sized businesses. The company was incorporated in 2000 and is headquartered in Sunnyvale, California.
Receive News & Ratings for Datasea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Datasea and related companies with MarketBeat.com's FREE daily email newsletter.
Fortinet remains a Buy, driven by robust billings growth, accelerating product sales, and strong margin performance across its hybrid security model. FTNT's deferred revenue reached $7.68B, with management guiding for 25% billings growth and 19% revenue growth, underpinned by recurring service contracts. Operating leverage is evident: non-GAAP operating margin hit 38%, adjusted free cash flow margin reached 49%, and free cash flow more than tripled year-over-year.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Pentair plc (“Pentair” or the “Company”) (NYSE: PNR) of the October 2, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.
Should You Join The Pentair Class Action Lawsuit:
Do you, or did you, own shares of Pentair plc (NYSE: PNR)?
Did you purchase your shares between March 11, 2025 and July 14, 2026, inclusive?
Did you lose money in your investment in Pentair plc?
What To Do Next:
Investors are encouraged to act promptly and submit a form at Pentair plc Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].
If you wish to serve as lead plaintiff for the Class, you must file papers by October 2, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About The Lawsuit:
A lawsuit was filed on behalf of investors (the “Class”) who purchased or acquired the ordinary shares of Pentair between March 11, 2025 and July 14, 2026, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, Pentair securities traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
Philadelphia, Pennsylvania--(Newsfile Corp. - September 8, 2026) - Berger Montague, a leading national plaintiffs' law firm, announces a class action lawsuit against Pentair plc (NYSE: PNR) ("Pentair" or the "Company") on behalf of investors who purchased or acquired Pentair securities during the period from March 11, 2025 through July 14, 2026 (the "Class Period").
Q&A
What is this lawsuit about?
According to the complaint, between March 11, 2025 and July 14, 2026, Pentair and certain executives failed to disclose that: (1) there was significant destocking of inventory in the Pool channel; and (2) as a result, the Company's sales and operating income were adversely affected. The truth allegedly began to emerge on July 14, 2026, after the market closed, when Pentair announced preliminary second quarter 2026 financial results, disclosing that Pool channel destocking had reduced Pool segment sales by approximately $170 million and Pool segment income by approximately $105 million. As a result, second quarter 2026 sales were expected to be down 17 percent versus the prior guide of approximately 1 percent growth, and full year 2026 sales were expected to be down approximately 4 percent to 7 percent versus the prior guide of up 2 percent to 4 percent. Pentair also announced the immediate departure of its Chief Financial Officer. On this news, Pentair's stock price fell $11.35, or 15%, to close at $64.33 per share on July 15, 2026, on unusually heavy trading volume.
Who is Pentair?
Pentair plc, headquartered in London, describes itself as a leader in helping the world sustainably move, improve, and enjoy water. The Company operates through three segments: Flow, Water Solutions, and Pool. The Pool segment designing and selling residential and commercial pool equipment, including pumps, filters, heaters, and automatic controls.
What do I need to do?
Investor Deadline: Investors who purchased or acquired Pentair securities during the Class Period may, no later than October 2, 2026, seek to be appointed as a lead plaintiff representative of the class.
To learn more or discuss your rights, contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015 or Caitlin Adorni at [email protected] or (267) 764-4865 or visit our website.
About Berger Montague
Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313209
Source: Berger Montague
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in Pentair plc (NYSE: PNR) that a class action has been filed on behalf of shareholders who purchased securities between April 28, 2026 and July 14, 2026. Find out if you could qualify to recover your per-share losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
PNR closed at $75.68 on July 14, 2026. After the guidance revision, the stock fell $11.35 per share, or 15%, on unusually heavy trading volume to close at $64.33. The last day to move for lead plaintiff is October 2, 2026.
The Promise
On April 28, 2026, the Company projected positive full year 2026 sales growth of approximately 2 to 4 percent, GAAP EPS of $4.83 to $4.93, and adjusted EPS of $5.30 to $5.40. Second quarter sales were guided up approximately 1 percent, with second quarter adjusted EPS of approximately $1.47 to $1.50.
The Reality
On July 14, 2026, after the market closed, the Company reported preliminary second quarter sales of approximately $930 million, down 17 percent against the previous guide, and revised full year sales guidance to project an approximate 4 to 7 percent decline. The lawsuit maintains that the April guidance omitted significant destocking of inventory in the Pool channel that was already affecting sales and operating income.
Promise vs. Actual: By the Numbers
Full year 2026 sales: promised up 2 to 4 percent; revised to down 4 percent to 7 percentQ2 2026 sales: guided up approximately 1 percent; reported down 17 percent, at approximately $930 millionFull year GAAP EPS: promised $4.83 to $4.93; revised to $3.90 to $4.10Full year adjusted EPS: promised $5.30 to $5.40; revised to $4.60 to $4.80Q2 adjusted EPS: guided $1.47 to $1.50; reported approximately $1.12Pool channel destocking impact: approximately $170 million in Q2 segment sales and $105 million in segment income; approximately $250 million in sales and $155 million in income for the full year Plaintiffs assert that the gap between the April projections and the July results reflects conditions that existed when the earlier guidance was issued, rather than developments that arose afterward.
"When a company reduces full year adjusted earnings guidance from $5.30 to $5.40 down to $4.60 to $4.80 within a few weeks, investors are entitled to ask what was known internally at the time of the original projection. The complaint alleges the Pool channel inventory situation was material and undisclosed." -- Joseph E. Levi, Esq.
Submit your information here or call (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the PNR Lawsuit
Q: What specific misstatements does the PNR lawsuit allege? A: The complaint alleges Pentair made materially false or misleading statements regarding inventory conditions and full year 2026 financial guidance during the Class Period, failing to disclose significant destocking in the Pool channel. When the Company disclosed that Pool channel destocking reduced segment sales by approximately $170 million and cut full year guidance, the stock price declined sharply.
Q: How much did PNR stock drop? A: Shares fell approximately 15%, a decline of $11.35 per share, after the Company disclosed preliminary second quarter results, revised full year 2026 guidance, and a CFO departure. Investors who purchased during the Class Period at artificially inflated prices and suffered losses may be eligible to seek compensation.
Q: Who are the defendants named in the PNR lawsuit? A: The complaint names Pentair plc and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What do PNR investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Contact SueWallSt, a brand of Levi & Korsinsky LLP, for a no-cost, no-obligation case evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as an absent class member.
Q: What if I already sold my PNR shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution. Timing depends on the court schedule, case developments, and whether the matter is dismissed, settled, or litigated further.
ATLANTA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Pentair plc (“Pentair”) (NYSE: PNR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there was significant destocking of inventory in its Pool channel; (2) as a result, Pentair’s sales and operating income were adversely affected.
If you purchased Pentair shares between April 28, 2026 and July 14, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/pentair/ for more information.
The deadline to ask the court to be appointed lead plaintiff in the case is October 2, 2026.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free) [email protected]
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pentair To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Pentair between March 11, 2025 and July 14, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - September 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pentair plc ("Pentair" or the "Company") (NYSE: PNR) and reminds investors of the October 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that there was significant destocking of inventory in the Pool channel; (2) that, as a result, the Company's sales and operating income were adversely affected; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On July 14, 2026, after the market closed, Pentair released its preliminary second quarter 2026 financial results, disclosing that "the [C]ompany estimates that the destocking of inventory in the Pool channel negatively impacted Pool segment sales by approximately $170 million and Pool segment income by approximately $105 million."1 As a result, second quarter 2026 sales were expected to be "down 17 percent versus the prior guide of approximately 1 percent" and full year 2026 "[s]ales are expected to be down approximately 4 percent to 7 percent versus prior guide of up 2 percent to 4 percent[.]" The Company also announced the departure of its Chief Financial Officer, effective immediately.
On this news, Pentair's stock price fell $11.35, or 15%, to close at $64.33 per share on July 15, 2026, on unusually heavy trading volume.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Pentair's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Pentair class action, go to www.faruqilaw.com/PNR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Pentair Securities Class Action Lawsuit:
What is the Pentair securities fraud lawsuit about?
The lawsuit alleges Pentair misled investors by failing to disclose significant inventory destocking in its Pool channel and the resulting negative impact on sales, operating income, and business prospects.
Who may be eligible to participate in the lawsuit?
Investors who purchased Pentair plc (NYSE: PNR) securities between March 11, 2025 and July 14, 2026 may be eligible to participate if they suffered losses.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff represents the proposed class during the litigation. Eligible investors must file a motion with the court by October 2, 2026. Investors may participate without serving as lead plaintiff.
What should investors do if they purchased Pentair stock during the Class Period?
Investors should review their trading records and consider consulting counsel about their legal rights, participation in the lawsuit, or seeking appointment as lead plaintiff.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Pentair securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313372
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Pentair plc (“Pentair” or the “Company”) (NYSE: PNR) securities between March 11, 2026 and July 14, 2026 inclusive (the “Class Period”).
IF YOU SUFFERED A LOSS ON YOUR PENTAIR PLC INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.
What Happened?
On July 14, 2026, after the market closed, Pentair released its preliminary second quarter 2026 financial results, disclosing that “the [C]ompany estimates that the destocking of inventory in the Pool channel negatively impacted Pool segment sales by approximately $170 million and Pool segment income by approximately $105 million.” As a result, second quarter 2026 sales were expected to be “down 17 percent versus the prior guide of approximately 1 percent” and full year 2026 “[s]ales are expected to be down approximately 4 percent to 7 percent versus prior guide of up 2 percent to 4 percent[.]” The Company also announced the departure of its Chief Financial Officer, effective immediately.
On this news, Pentair’s stock price fell $11.35, or 15%, to close at $64.33 per share on July 15, 2026, on unusually heavy trading volume.
What Is The Lawsuit About?
The complaint filed in this class action alleges that between March 11, 2026 and July 14, 2026, Defendants failed to disclose to investors: (1) that there was significant destocking of inventory in the Pool channel; (2) that, as a result, the Company’s sales and operating income were adversely affected; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you purchased or otherwise acquired Pentair plc securities between March 11, 2026 and July 14, 2026, you may move the Court no later than October 2, 2026 to request appointment as lead plaintiff in this putative class action lawsuit
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Pentair plc.
IF YOU SUFFERED A LOSS ON YOUR PENTAIR PLC INVESTMENTS, CLICK HERE BEFORE OCTOBER 2, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
What Is The Lawsuit About?
The complaint filed in this class action alleges that between March 11, 2026 and July 14, 2026, Defendants failed to disclose to investors: (1) that there was significant destocking of inventory in the Pool channel; (2) that, as a result, the Company's sales and operating income were adversely affected; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What's The Next Step?
Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist you in potentially pursuing claims to recover your loss.
If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2026. Please contact us to learn more about your rights and interests by clicking here, by email ([email protected]), or by telephone at 310-201-9150 (Toll-Free: 888-773-9224).
You may retain counsel of your choice. If you bought securities during the class period, you may take no action and remain an absent class member. No class has been certified yet.
Why Glancy Prongay Wolke & Rotter LLP?
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked 2nd in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Pentair plc ("Pentair" or the "Company") (NYSE: PNR) on behalf of investors that purchased or otherwise acquired Pentair securities between April 28, 2026 and July 14, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Pentair and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 2, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
The complaint alleges that on July 14, 2026, after the market closed, Pentair released its preliminary second quarter 2026 financial results, disclosing that "the [C]ompany estimates that the destocking of inventory in the Pool channel negatively impacted Pool segment sales by approximately $170 million and Pool segment income by approximately $105 million." The Company also announced the departure of its Chief Financial Officer, effective immediately. On July 15, 2026, Pentair's stock price fell $11.35, or 15%, to close at $64.33 per share.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Pentair plc (“Pentair” or the “Company”) (NYSE: PNR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Pentair and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until October 2, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Pentair securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On July 14, 2026, Pentair issued a press release announcing its preliminary second quarter 2026 financial results and revising its full year 2026 guidance. For the second quarter, Pentair reported that “[s]ales are expected to be approximately $930 million, down 17 percent versus previous guide of up approximately 1 percent primarily due to the adverse impact of Pool channel inventory” and that “[e]arnings per diluted share from continuing operations (‘EPS’) are expected to be approximately $0.80 versus previous guidance of $1.39 to $1.42; Adjusted EPS is expected to be approximately $1.12 versus previous guide of $1.47 to $1.50 as the result of the adverse impact of Pool channel inventory and the positive impact of IEEPA refunds”. Pentair also lowered its full year 2026 guidance, advising that “[s]ales are expected to be down approximately 4 percent to 7 percent versus previous guide of up 2 percent to 4 percent mostly attributable to destocking of inventory in the Pool channel and right sizing of channel inventory in preparation for the 2027 pool season”. The press release also announced the departure of Chief Financial Officer Nicholas Brazis, “to pursue another opportunity at a private company.”
On this news, Pentair’s stock price fell $11.35 per share, or 15%, to close at $64.33 per share on July 15, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
San Francisco, California--(Newsfile Corp. - September 8, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in Pentair plc (NYSE: PNR) that a securities fraud class action lawsuit filed against the company has been expanded to cover an earlier class period. Investors who suffered substantial losses are urged to submit their losses now.
CASE DETAILS
Expanded Class Period: March 11, 2025 - July 14, 2026 (Previously April 28, 2026 - July 14, 2026)
Lead Plaintiff Deadline: Oct. 2, 2026
Contact Hagens Berman: Visit www.hbsslaw.com/pnr, email [email protected], or call (844) 916-0895
ALLEGED MISCONDUCT & EXPANDED CLASS PERIOD
The new class action lawsuit alleges that beginning on March 11, 2025, Pentair plc and certain of its top executives made a series of materially false and misleading statements and omitted critical adverse operational information regarding Pentair's financial health, channel inventory, and internal controls.
Specifically, the lawsuit alleges Defendants failed to disclose that:
Pentair was experiencing severe, undisclosed channel inventory destocking-particularly within its core Pool segment. The company engaged in unsustainable channel-loading and sales practices with distributors to artificially inflate short-term financial metrics. As a result, Pentair's positive statements regarding its business, full-year financial guidance, and operating income lacked a reasonable basis.THE DISCLOSURE & MARKET REACTION
The complaint alleges that the artificial inflation in Pentair shares came to an abrupt end on July 14, 2026, after the market closed, when Pentair shocked investors by pre-announcing preliminary second-quarter 2026 financial results that fell substantially below consensus estimates.
The disclosures revealed severe operational headwinds:
Massive Revenue Miss: Sales were expected to be approximately $930 million-a drastic miss against prior forecasts of $1.14 billion. The company disclosed that inventory destocking in the Pool channel negatively impacted Pool segment sales by approximately $170 million and income by approximately $105 million.Full-Year Guidance Slashed: Pentair dramatically cut its full-year 2026 outlook, reversing earlier projections. Full-year sales were projected to be down approximately 4% to 7%, compared to prior guidance of up 2% to 4% growth.Abrupt CFO Departure: Compounding the shock, Pentair announced the immediate departure of its Chief Financial Officer, Nicholas Brazis, after serving in the role for only four months, raising questions regarding internal controls and financial reporting.Following these disclosures, Pentair's stock price plummeted 15% in a single session-losing $11.35 per share to close at $64.33 on unusually heavy trading volume on July 15, 2026.
"We are closely examining the timing of these disclosures, the sudden departure of the CFO after only four months, and the severe impact of channel destocking on Pentair's financial health," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claims.
What Affected PNR Investors Should Do
If you purchased or acquired Pentair common stock between March 11, 2025, and July 14, 2026, and suffered significant financial losses, you have until October 2, 2026, to ask the court to appoint you as lead plaintiff.
To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/pnr, call Reed Kathrein at 844-916-0895, or email [email protected].
If you'd like more information and answers to other frequently asked questions about the Pentair case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding Pentair should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
# # #
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313508
Source: Hagens Berman Sobol Shapiro LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pentair plc (NYSE: PNR) between April 28, 2026 and July 14, 2026, inclusive (the "Class Period"), of the important October 2, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Pentair securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Pentair class action, go to https://rosenlegal.com/cases/pentair-plc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and or failed to disclose that: (1) there was significant destocking of inventory in the Pool channel; (2) as a result, Pentair's sales and operating income were adversely affected; and (3) as a result of the foregoing, defendants' positive statements about Pentair's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Pentair class action, go to https://rosenlegal.com/cases/pentair-plc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313577
Source: The Rosen Law Firm PA
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Devon Energy (DVN) receives a reiterated buy rating, supported by strong Q2 results and robust operational execution post-Coterra merger. DVN beat Q2 guidance, generated $1.655 billion adjusted FCF, and returned over $1 billion to shareholders via debt reduction, buybacks, and a raised dividend. Management targets $1 billion in annual run-rate synergies and projects FY 2026 EPS growth near 40% to $5.42, with a tightened production outlook.
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.
Phase 3 HARBOR Trial Misses Primary EndpointOn Tuesday, the company shared data from the global Phase 3 HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM1).
The study did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia.
Myotonia is a neuromuscular condition where muscles are unable to relax right away after a voluntary contraction or strong effort.
Read Next
Safety findings from HARBOR were generally consistent with previously reported data.
Novartis is evaluating the full HARBOR dataset and will engage with health authorities to determine the most appropriate development path for del-desiran.
Del-desiran is one of three antibody-oligonucleotide conjugate (AOC) therapies added to the Novartis neuromuscular pipeline through the acquisition of Avidity Biosciences for a whopping $12 billion.
Status of $12 Billion Avidity Pipeline AcquisitionNovartis is advancing delpacibart zotadirsen (del-zota) in patients with Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44).
The company filed del-zota for accelerated approval and received FDA priority review designation.
Novartis is planning to meet with the FDA on next steps for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) based on recent positive Phase 1/2 biomarker data.
Pelacarsen Cardiovascular Trial FailsOn Friday, Novartis also shared another trial disappointment after it released data from the pelacarsen phase 3 Lp(a)HORIZON trial, a cardiovascular outcomes study.
The study did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo.
Lower lipoprotein (a) (Lp(a)) levels were achieved with pelacarsen in this study population, which was receiving guideline-directed treatments, including lipid-lowering and antihypertensive therapies.
Elevated Lp(a) is an inherited cardiovascular risk factor affecting approximately one in five people worldwide with no approved targeted treatment.
Ripple Effect Hits PartnersAfter the update, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock also tanked as Novartis obtained global rights to develop, manufacture, and commercialize pelacarsen under a 2019 license and collaboration agreement.
In 2023, Royalty Pharma plc (NASDAQ:RPRX) acquired an interest in Ionis’ royalty in Biogen’s SPINRAZA (nusinersen) and Novartis’ pelacarsen for up to $1.125 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments.
After the disappointing trial data, Royalty Pharma stock is also trading lower on Tuesday.
NVS/IONS/RPRX Stock Price Activity: Novartis shares were down 12.57% at $139.88, Ionis Pharmaceuticals shares were down 9.80% at $52.40, and Royalty Pharma shares were down 6.29% at $59.94 during premarket trading Tuesday, according to Benzinga Pro data.
Olivier Le Peuch, Chief Executive Officer of SLB N.V. (SLB -0.71%), disclosed a sale of 5,000 shares on Aug. 31, 2026, according to a recent SEC Form 4 filing.
Transaction summaryMetricValueTransaction value$300,000Shares sold (directly held)5,000Post-transaction shares (directly held)1,331,328Post-transaction value$80.01 millionTransaction value based on SEC Form 4 weighted average sale price ($60.00); post-transaction value based on Aug. 31, 2026 market close ($60.10).
Key questionsWhat was the mechanism for this transaction?
The sale was conducted under a Rule 10b5-1 trading plan adopted by the Chief Executive Officer on May 27, 2026, which allows insiders to schedule trades in advance to manage liquidity and diversify holdings.What is the extent of the executive's remaining equity holdings?
Following this transaction, the reporting owner continues to hold a direct position of 1,331,328 shares in the energy technology company, valued at $80.01 million as of the Aug. 31, 2026, market close.How has the stock performed relative to the transaction date?
Shares of the company were priced at $60.00 in this transaction, while the equity has delivered a total return of 63% over the one-year period ending on Aug. 31, 2026.What is the broader ownership context for this executive?
The executive's direct equity holdings represent approximately 0.0897% of the company's total shares outstanding, and the company provides technology and services to the global energy industry across four primary divisions.Company OverviewMetricValueShare Price (as of market close 2026-08-28)$57.33Market Capitalization$85.1 billionRevenue (TTM)$36.4 billionNet Income (TTM)$3.1 billionCompany SnapshotSLB N.V. provides integrated technology solutions and services for the energy industry, including field development, hydrocarbon production optimization, carbon management, reservoir interpretation, well construction, and production improvement systems across four primary operating divisions.The company generates revenue through a diversified business model encompassing technology licensing, equipment sales, professional services, and integrated solutions that address the full lifecycle of oil and gas field development and production operations.SLB serves major integrated oil and gas companies, independent producers, and national oil companies globally, positioning itself as a critical technology and services partner for energy production and carbon management initiatives worldwide.SLB N.V. is a leading global provider of technology and services to the energy industry, operating at a significant scale with 109,000 employees and generating $36.4 billion in TTM revenue. The company's competitive advantage derives from its integrated technology platform spanning digital solutions, reservoir performance optimization, well construction, and production systems, enabling customers to maximize hydrocarbon recovery while advancing carbon management objectives. With a market capitalization of $85.1 billion and strong profitability generating $3.1 billion in TTM net income, SLB maintains a strategic position to capitalize on both conventional energy production and the energy transition.
What this transaction means for investorsInsider transactions can be confusing to the average investor. That's because they're often triggered by tax considerations, estate planning, or some other esoteric form of wealth management. To cut through the noise, it's best for investors to focus on a company's fundamentals. With that in mind, let's have a look at SLB.
To begin, we should review SLB's recent performance relative to the broader stock market. Since 2021, SLB has generated a total return (change in price plus dividend payments) of 131%, equating to a compound annual growth rate (CAGR) of 18.2%. The S&P 500, meanwhile, has delivered an 83% total return, with a 12.8% CAGR.
Premium Feature
Moneyball Superscore
78/100
Today's Change
(
-0.71
%) $
-0.41
Current Price
$
57.10
As for fundamentals, most look excellent. Free cash flow, for example, stands at $4.5 billion. That's almost a five-year high ($5.1 billion), well above the five-year average of $3.7 billion and the five-year low of $2.0 billion. Similarly, SLB's revenue is outstanding. Its trailing 12-month revenue is $36.3 billion, an all-time high. Moreover, SLB has averaged 11.3% year-over-year revenue growth since 2021.
On the flip side, net income has not kept pace with revenue. Net income reached a five-year peak of $4.6 billion in 2024. Since then, net income has pulled back to $3.2 billion, as the company has faced integration headwinds from recent acquisitions. What's more, ongoing geopolitical tensions in the Middle East continue to weigh on the company's profit margins.
In summary, SLB's core metrics are mixed, although some have been affected by temporary factors (such as integration costs or geopolitical fallout). Therefore, investors would still be wise to consider SLB, given its strong free cash flow and resilient business model.
Cameco (CCJ +1.22%) owns the largest commercial uranium refinery in the world. And it's not in Kazakhstan, China, or Russia. It's in Blind River, Ontario, Canada.
The Blind River refinery takes uranium concentrate (commonly called yellowcake) and removes impurities to produce uranium trioxide, or UO3. That material is then shipped to Cameco's Port Hope facility, where it's converted into what ultimately becomes nuclear fuel. Blind River currently has a production capacity of 18 million kilograms of uranium annually and is licensed for up to 24 million kilograms. Indeed, Cameco is much more than just a uranium miner.
Cameco controls more of the fuel cycle Mining uranium is only the beginning of the nuclear fuel cycle. Before uranium can fuel most reactors, it has to be refined, converted, and, depending on the reactor, enriched and fabricated into fuel rods. Cameco participates in several of those steps.
Today's Change
(
1.22
%) $
1.23
Current Price
$
101.97
After uranium is refined at Blind River, much of the UO3 travels to Cameco's Port Hope Conversion Facility. Port Hope converts it into either uranium hexafluoride, or UF6, which can be enriched for light-water reactors, or uranium dioxide (UO2), which is used to produce fuel for Canada's CANDU reactors, which are heavy water (deuterium oxide) reactors.
Now you have to understand that Port Hope would be particularly difficult to replace. It's Canada's only uranium conversion facility, one of only a handful of Western suppliers of UF6, and the world's only commercial supplier of natural UO2 used in CANDU reactors. That's a strategic position few nuclear companies can match. And demand is strong.
Cameco produced 6.3 million kilograms of fuel-services products during the first half of 2026 and still expects to produce between 13 million and 14 million kilograms for the full year. Those facilities aren't sitting around waiting for customers, either. Cameco entered 2026 with contracts covering roughly 83 million kilograms of UF6 conversion services for 33 utilities around the world.
Image source: Getty Images.
A different way to invest in nuclear power This is one of the reasons I continue to like Cameco as a long-term nuclear investment. You see, companies like Oklo (OKLO +4.94%) and NuScale (SMR +15.26%) need to successfully commercialize new reactor designs before they can generate substantial reactor-related revenue. Cameco doesn't need to predict which advanced reactor company will ultimately win the race to commercialize its designs.
Existing nuclear plants need fuel today. New reactors will need fuel tomorrow. Cameco can sell the uranium, refine it, convert it, manufacture CANDU fuel, and, through its stake in Westinghouse Electric Company, participate in the reactor business itself.
Understandably, the Blind River refinery and Port Hope conversion facility won't generate the excitement of a new small modular reactor. But they occupy critical positions in a Western nuclear fuel supply chain that's becoming increasingly valuable as electricity demand rises and utilities look to nuclear power for reliable, around-the-clock generation. And of course, more nuclear generation means more demand for uranium, conversion services, and nuclear fuel -- exactly the parts of the supply chain Cameco already controls.
Canada might not be literally unable to survive without these facilities. But replacing them would be extraordinarily difficult. And that gives Cameco a very real and strategic advantage as the global energy economy continues to rapidly expand.
McCormick & Company, Incorporated (NYSE:MKC – Get Free Report) saw some unusual options trading activity on Tuesday. Stock investors bought 3,902 call options on the stock. This represents an increase of 94% compared to the typical daily volume of 2,016 call options.
Wall Street Analysts Forecast Growth A number of analysts have weighed in on the company. TD Cowen reduced their target price on McCormick & Company, Incorporated from $64.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. JPMorgan Chase & Co. dropped their price objective on shares of McCormick & Company, Incorporated from $64.00 to $63.00 and set an “overweight” rating on the stock in a report on Friday, June 12th. Jefferies Financial Group dropped their price target on shares of McCormick & Company, Incorporated from $64.00 to $62.00 and set a “buy” rating on the stock in a research report on Thursday, June 4th. UBS Group upped their price objective on shares of McCormick & Company, Incorporated from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Friday, June 26th. Finally, Barclays lowered their target price on shares of McCormick & Company, Incorporated from $57.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Friday, June 26th. Six equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $60.50.
Read Our Latest Research Report on McCormick & Company, Incorporated
Insider Activity In other McCormick & Company, Incorporated news, major shareholder Lawrence Kurzius sold 205,538 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $52.69, for a total transaction of $10,829,797.22. Following the completion of the transaction, the insider owned 296,992 shares in the company, valued at $15,648,508.48. The trade was a 40.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.60% of the stock is owned by company insiders. Institutional Inflows and Outflows A number of hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System grew its holdings in shares of McCormick & Company, Incorporated by 4,040.2% during the second quarter. California State Teachers Retirement System now owns 22,290,279 shares of the company’s stock valued at $1,123,876,000 after purchasing an additional 21,751,887 shares during the last quarter. Aristotle Capital Management LLC grew its stake in McCormick & Company, Incorporated by 231.9% in the 1st quarter. Aristotle Capital Management LLC now owns 12,664,378 shares of the company’s stock valued at $638,795,000 after buying an additional 8,848,235 shares during the last quarter. XXEC Inc. bought a new position in McCormick & Company, Incorporated in the 2nd quarter worth approximately $154,566,000. Invesco Ltd. raised its stake in shares of McCormick & Company, Incorporated by 66.7% in the third quarter. Invesco Ltd. now owns 6,232,337 shares of the company’s stock valued at $417,006,000 after purchasing an additional 2,494,544 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of McCormick & Company, Incorporated by 67.2% during the 3rd quarter. Wellington Management Group LLP now owns 2,797,533 shares of the company’s stock valued at $187,183,000 after acquiring an additional 1,124,003 shares in the last quarter. Institutional investors and hedge funds own 79.74% of the company’s stock.
McCormick & Company, Incorporated Stock Down 0.3% McCormick & Company, Incorporated stock opened at $51.94 on Wednesday. The stock’s fifty day moving average is $52.95 and its two-hundred day moving average is $52.82. The stock has a market cap of $13.96 billion, a PE ratio of 8.64, a P/E/G ratio of 2.05 and a beta of 0.64. McCormick & Company, Incorporated has a 1-year low of $44.82 and a 1-year high of $72.41. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.78 and a quick ratio of 0.39.
McCormick & Company, Incorporated (NYSE:MKC – Get Free Report) last issued its quarterly earnings data on Thursday, June 25th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.11. The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.91 billion. McCormick & Company, Incorporated had a return on equity of 12.78% and a net margin of 21.91%.The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.69 earnings per share. McCormick & Company, Incorporated has set its FY 2026 guidance at 3.050-3.130 EPS. On average, sell-side analysts expect that McCormick & Company, Incorporated will post 3.08 EPS for the current fiscal year.
McCormick & Company, Incorporated Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Monday, July 20th. Investors of record on Monday, July 6th were given a $0.48 dividend. The ex-dividend date was Monday, July 6th. This represents a $1.92 annualized dividend and a dividend yield of 3.7%. McCormick & Company, Incorporated’s payout ratio is currently 31.95%.
(Get Free Report)
McCormick & Company, Incorporated (NYSE: MKC) is a global leader in spices, seasonings and flavor solutions. Headquartered in Hunt Valley, Maryland, the company traces its origins to the late 19th century and has grown into a major manufacturer and marketer of branded and private‑label flavor products for consumer, industrial and foodservice markets.
McCormick’s product portfolio includes pure spices and herbs, blended seasonings, marinades, rubs, sauces, extracts and specialty flavorings, along with ingredient systems and custom flavor development for manufacturers and foodservice operators.
See Also Five stocks we like better than McCormick & Company, Incorporated Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Receive News & Ratings for McCormick & Company Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McCormick & Company Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
SARASOTA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Piper Sandler Growth Frontiers Conference on Tuesday, September 15, 2026, at 8:30 AM (Central Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at www.ropertech.com.
About Roper Technologies
Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company’s website at www.ropertech.com.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Cardinal Health (CAH - Free Report) Headquartered in Dublin, OH, Cardinal Health, Inc. is one of the world’s largest healthcare services and products providers, operating across Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and three Other growth businesses. The company serves nearly 90% of U.S. hospitals, delivers more than 43,000 pharmaceutical shipments daily, and manages a broad portfolio of medical, surgical, laboratory, and healthcare logistics offerings.
CAH is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 19.7; value investors should take notice.
Nine analysts revised their earnings estimate upwards in the last 60 days for fiscal 2027. The Zacks Consensus Estimate has increased $0.57 to $12.55 per share. CAH boasts an average earnings surprise of +14.7%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, CAH should be on investors' short list.
Key Takeaways CAH is integrating technology across distribution, specialty services, patient support and logistics.Sonexus now connects with Nuclear's web-ordering platform for an end-to-end digital workflow.CAH expects $700 million in fiscal 2027 capital spending, including infrastructure and technology. Cardinal Health’s (CAH - Free Report) fiscal 2026 results suggest that technology is becoming an increasingly important layer across its healthcare infrastructure, complementing its traditional distribution capabilities. The company has invested heavily in automation, technology and advanced analytics across its distribution network, with management citing meaningful gains in efficiency and service performance. These investments are translating into measurable operational benefits: Cardinal’s total fill rate reached nearly 99%, while the company recorded its best quarter for on-time departures.
The transformation is particularly visible in Sonexus, Cardinal Health’s specialty access and patient-support business. Rather than operating Sonexus as a standalone service, Cardinal Health has integrated it directly into the Nuclear business’ web-ordering platform. The result is an end-to-end digital workflow for high-cost radiopharmaceuticals, combining insurance-benefit verification, patient enrollment and order placement within a single system. This integration potentially reduces friction across a highly complex healthcare transaction while improving the experience for providers and patients.
Technology is also reshaping Cardinal Health’s logistics offering. OptiFreight is expanding its technology-enabled products, including Shipment Navigator and Tracking Beacon, which are designed to provide customers with greater visibility and insights into outbound pharmacy shipments. Management said adoption has been strong, as these solutions are built to generate cost savings and efficiency for healthcare providers.
The broader strategy is therefore moving beyond simply distributing pharmaceuticals and medical products. Cardinal Health is increasingly connecting distribution, specialty services, patient support and logistics through digital workflows. Its Consumer Health Logistics Center, meanwhile, has used technology and automation to improve service levels and customer access.
The financial opportunity lies in making these investments scalable. Cardinal expects $700 million of fiscal 2027 capital expenditures, including infrastructure and technology investments supporting future growth. If technology continues improving throughput, accuracy, customer experience and supply-chain visibility, Cardinal Health could increasingly operate as a tech-enabled healthcare platform rather than a conventional distributor.
Peer UpdatesCONMED (CNMD - Free Report) is building its technology proposition around AirSeal, using differentiated surgical technology and clinical evidence to improve procedure efficiency and outcomes. AirSeal’s low-pressure insufflation platform is designed to improve visualization, reduce procedure times, postoperative pain and length of stay, making it increasingly relevant as robotic surgery expands across specialties and ASCs. CONMED is also generating ASC-specific economic data and expanding clinical relationships in laparoscopic applications such as colorectal and gynecology. With AirSeal currently used in only 6-7% of more than 3 million U.S. laparoscopic procedures, the company has substantial room to expand utilization. Management expects long-term AirSeal growth of high-single-digit to low-double-digit rates.
Align Technology (ALGN - Free Report) is developing a broader digital healthcare platform that connects imaging, diagnostics, treatment planning and treatment delivery. Its Align Digital Platform integrates iTero scanners, Invisalign, exocad and X-ray Insight software, creating a connected workflow spanning orthodontic and restorative dentistry. New platform capabilities are designed to improve patient engagement, treatment planning and workflow efficiency, while software, visualization, digital planning and 3D printing help doctors increase practice productivity. The strategy is also expanding the installed scanner base through lower-cost configurations, leasing and rental models, which can increase digital adoption and create a larger funnel for higher-margin, recurring treatment revenue. With active scanner units up 11% year over year and scans rising 16%, growing platform utilization could reinforce Align’s long-term competitive moat.
CAH’s Price Performance, Valuation and EstimatesShares of CAH have gained 17.5% so far this year compared with the industry’s 7.3% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings of 19.2X, above the industry average. However, it is trading lower than its five-year high of 22.19X. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2027 earnings implies an 11.5% rise from the year-ago reported number.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the latest trading session, Cardinal Health (CAH - Free Report) closed at $240.49, marking a -2.71% move from the previous day. This move lagged the S&P 500's daily loss of 0.58%. On the other hand, the Dow registered a loss of 1.18%, and the technology-centric Nasdaq decreased by 0.32%.
The stock of prescription drug distributor has risen by 4.22% in the past month, leading the Medical sector's gain of 2.73% and the S&P 500's loss of 0.36%.
The investment community will be paying close attention to the earnings performance of Cardinal Health in its upcoming release. It is anticipated that the company will report an EPS of $2.92, marking a 14.51% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $66.96 billion, up 4.6% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $12.55 per share and a revenue of $266.02 billion, indicating changes of +11.46% and +4.63%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Cardinal Health. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 4.23% higher. Cardinal Health presently features a Zacks Rank of #3 (Hold).
Digging into valuation, Cardinal Health currently has a Forward P/E ratio of 19.7. This indicates a premium in contrast to its industry's Forward P/E of 18.24.
One should further note that CAH currently holds a PEG ratio of 1.49. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical - Dental Supplies industry stood at 1.82 at the close of the market yesterday.
The Medical - Dental Supplies industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 75, placing it within the top 31% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Lucid stock has cratered while rivals like Tesla and Rivian held their ground, and the company's latest financials reveal a tension between surging revenue and an alarming cash burn that puts every investor's next move under pressure.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Lucid Group (NASDAQ:LCID | LCID Price Prediction) stock has fallen 33% over the past month to $4.70, leaving investors to decide whether the sharp decline represents a warning sign or a potential opportunity. Lucid stock has severely lagged several major electric-vehicle names, with the latest drop coming as the company works through an operational reset while trying to conserve cash and build demand.
Lucid’s second-quarter results provide arguments for both sides. The automaker generated $405 million of quarterly revenue, up 56% year over year, while deliveries rose 19% to 3,953 vehicles, but Lucid also reported a major cash-burn problem and acknowledged the need to reduce production and inventory.
Lucid Stock Has Fallen Far Behind Its Peers Lucid stock’s 33% one-month decline looks particularly painful next to the performance of other electric-vehicle stocks. Rivian Automotive (NASDAQ:RIVN) stock is up 0.87% over the same period to $16.14, while Tesla (NASDAQ:TSLA) stock is up 11% to $366.11.
Tesla has also been dealing with uneven electric vehicle (EV) demand, including a slowdown in the growth of China-made vehicle sales during August, but Tesla’s scale and broader business give Tesla stock a very different risk profile from Lucid stock. Rivian likewise has a larger production base, leaving Lucid with a much smaller margin for execution mistakes as Lucid tries to reach the next stage of its growth plan.
The EV ETF Has Held Up Better The broader EV and autonomous-driving theme hasn’t suffered nearly as much as Lucid stock. The Global X Autonomous & Electric Vehicles ETF (NASDAQ:DRIV) is down 2% over the past month to $34.89, meaning Lucid stock has underperformed the thematic ETF by a wide margin.
The DRIV ETF offers exposure across electric vehicles, autonomous-driving technology, components and related materials, which gives investors a much broader basket than a concentrated bet on Lucid. Tesla is among DRIV’s holdings, while the fund also includes companies such as NVIDIA (NASDAQ:NVDA) and Alphabet (NASDAQ:GOOGL), underscoring how much broader the autonomous-vehicle investment theme has become.
Lucid Has a Real Bull Case Lucid has several developments that could eventually support a recovery in Lucid stock. Lucid’s Gravity program is progressing, the company is working with Uber and Nuro on robotaxi testing, and Lucid has identified $1.4 billion of potential 2026 cash-flow improvements while targeting a midsize vehicle program for future growth.
However, Lucid’s financial position remains the biggest concern. Lucid ended the second quarter with $3 billion of total liquidity, but Lucid’s free cash flow was negative $1.476 billion, and management intentionally reduced production to lower inventory and preserve cash.
Selling Could Still Be The Safer Choice Lucid stock could rebound if the company’s cost-cutting efforts work, Gravity gains traction and the midsize vehicle program expands the addressable market. Investors may want to watch for whether Lucid can reduce cash burn while improving deliveries, because stronger revenue alone may not be enough to change the investment case.
However, the 33% monthly decline reflects serious concerns that may not disappear quickly. Investors who choose to hold Lucid stock should consider keeping their position sizes moderate, while investors without an existing position may prefer waiting for clearer evidence that Lucid’s operational reset is translating into stronger financial results.
Contact [email protected] for any questions or corrections.
Shares of the electric automaker Lucid (LCID -1.07%) plunged 34.2% last month, according to data provided by S&P Global Market Intelligence, after the company reported disappointing quarterly results.
Investors become increasingly concerned with Lucid's deepening losses and rising spending. A general slowdown in the electric vehicle market and increasing worries about tariffs aren't helping Lucid either.
Image source: The Motley Fool.
Lucid is fighting an uphill battle Lucid reported is second quarter results toward the beginning of August, and many investors immediately sold their shares following the company's poor quarterly performance.
Lucid managed to increase vehicle production by 24% in the quarter, deliveries rose by 19%, and revenue jumped 56% from the year-ago quarter. But all that was overshadowed by the company's adjusted net loss of $2.78 per share, far worse than Wall Street's consensus estimate of $2.41 per share.
And then there was Lucid's rising cash burn, which accelerated to about $1.5 billion in the quarter, up from just over $1 billion in the year-ago quarter. Investors were deeply concerned with the high spending and widening losses, and management's attempt to put financial fears to rest didn't work.
Lucid's leadership said that it has identified $1.4 billion of cash flow improvements in 2026 "across operating costs, capital spending, and working capital." But investors' rapid sell-off of Lucid stock in August indicates that they feel the move is too late, or that the company will have a hard time delivering on that goal.
One of the ongoing problems for Lucid is that the company hasn't been able to improve its margins, despite new capital, selling new models, and years of manufacturing. Adding to the problem in the quarter was a $300 million impairment charge "associated with inventory optimization actions."
Investors also didn't feel optimistic about where Lucid is headed, as management said it had slowed some vehicle production. Lucid CEO Silvio Napoli said on the company's earnings call,
"We deliberately reduced production by eliminating a second shift because building vehicles faster than we could deliver them was consuming cash and increasing inventory."
Lucid wants to convert its inventory into deliveries, which is good, but the slowed production in the quarter indicates that there's not enough demand for the company's existing inventory.
Premium Feature
Moneyball Superscore
51/100
Today's Change
(
-1.07
%) $
-0.05
Current Price
$
4.63
It's not going to get any easier If you're a Lucid shareholder, things aren't likely to get any easier for the company any time soon. The U.S. is currently in a trade war with Canada, and there have been threats between the countries about automotive tariffs being implemented as early as the beginning of 2027.
What's more, the EV industry is already struggling. Second-quarter EV sales in the U.S. were down by nearly 21% compared to the year-ago quarter, according to Kelley Blue Book data.
With the EV market struggling and Lucid floundering, it's not surprising to see its share price falling right now.
VANCOUVER, Wash.--(BUSINESS WIRE)--ZoomInfo (NASDAQ: GTM), the all-in-one AI GTM platform, has reported that Deal IQ, a Toronto-based procurement consulting firm that negotiates technology contracts on behalf of Fortune 500 companies, grew its annual revenue by more than 1900% using ZoomInfo, according to the company. Deal IQ also reported a 6X increase in its client portfolio and an 8X increase in C-suite meetings booked. Deal IQ negotiates the vendor contracts Fortune 500 companies do not hav.
VANCOUVER, Wash.--(BUSINESS WIRE)--ZoomInfo (NASDAQ: GTM), the all-in-one AI GTM platform, has reported that Exact Media, an ad agency and events company that connects brand advertisers with e-commerce retailers, expanded its complete-data prospect audience 20X using ZoomInfo, according to the company. The team also stood up the platform in 10 days from first call to first use. Exact Media runs a Connections platform that pairs brand advertisers with e-commerce retailers, and it organizes in-pe.
Pathward’s Credit Scare Tests Its Comeback StoryUpstart NASDAQ: UPST CEO Paul Gu said the company is concentrating its efforts on expanding its core personal loan business, which he described as the company’s most differentiated and highest-margin product. Gu said the segment’s growth accelerated in the second quarter, with core personal loan growth reaching roughly 3.5 times the growth recorded across the prior three quarters combined.
Gu, who previously served as Upstart’s chief technology officer, said the company has shifted internal priorities across marketing, application conversion, approvals, rate acceptance and verification to emphasize personal loans. He said the company had previously directed more resources toward other initiatives but has since refocused teams on increasing personal loan volume.
Get Upstart alerts:
MarketBeat Week in Review – 03/30 - 04/03“Core personal loans is what we’re really, really good at doing,” Gu said, citing the company’s ability to separate credit risk and identify borrowers it believes can be uniquely underwritten in the market.
Product Priorities and Secured Lending While Upstart continues to pursue newer products, Gu said the company has narrowed its list of priorities. He said Upstart paused its auto refinance product because it did not have the same potential, growth profile or momentum as other initiatives.
Upstart Surges on Record Revenue but Wall Street Remains DividedGu said the remaining product bets have large addressable markets, are adjacent to areas in which Upstart already has expertise, and have sufficient momentum to justify additional investment. The company’s secured lending products include auto lending and home equity lines of credit, or HELOCs.
For those newer secured products, Gu said Upstart first focused on validating demand and building third-party capital-provider relationships before turning to unit economics. He said the company believes it has demonstrated demand from auto dealerships and from HELOC borrowers seeking its rates and process.
Upstart is now working to move the secured products from negative contribution margins to profitability. Gu said the company expects those products to reach break-even before the end of the year, after which it plans to focus more heavily on scaling them. He declined to project their long-term margins but said there was no theoretical reason they could not eventually approach the economics of the core personal loan business.
Consumer Stress Remains Elevated Gu discussed the company’s Upstart Macro Index, or UMI, which measures the likelihood that consumers will default on unsecured consumer credit relative to pre-COVID levels. A reading of 1.0 corresponds to conditions in 2018, 2019 and early 2020, he said.
With the UMI at approximately 1.5 as of Sept. 3, Gu said a consumer with the same borrower and loan characteristics was about 50% more likely to default than before the pandemic. He said the index had risen by 12 points since the spring.
Gu attributed the pressure on borrowers in part to inflation exceeding wage growth over roughly the prior six months. He also cited credit card utilization and delinquency data as evidence that American borrowers are under more stress than they were six months earlier.
Still, Gu said investors should not place too much emphasis on short-term changes in the macro index. He said Upstart does not provide near-term results guidance partly because it wants to respond quickly to changing credit conditions. Over a multiyear period, he said, durable improvements in marketing, automation, underwriting and risk separation should matter more than monthly macroeconomic movements.
Gu said that despite higher interest rates and greater consumer stress than in 2021, Upstart is generating more contribution profit than it did during that more favorable macroeconomic period. He attributed that result to several years of technology improvements.
Technology, Capital and Bank Plans Gu said Upstart has continued to improve its lending models since its founding in 2012 and has not exhausted potential avenues for advancement. He said the company has more than 140 million training data points and expects additional data, computing improvements and research into learning algorithms to support increasingly sophisticated models over time.
He described the company as a relatively advanced adopter of artificial intelligence tools internally, saying the technology has contributed to more code being written and faster ticket resolution. Gu said he expects those gains to translate over time into greater revenue growth per employee, though he noted it can be difficult to attribute results precisely.
On funding, Gu said Upstart has retained all of its capital partners in recent years, with agreements being renewed for longer terms, larger amounts and generally better terms. He said the company has not seen evidence that competitors’ funding or marketing activity has materially hurt its ability to originate loans.
Gu also said the company’s planned national bank remains its largest single project in 2026. He said the bank has conditional approval and is expected to launch in early 2027. The investment will be a cost center in 2026, but Gu said it should provide operational benefits by reducing complexity associated with working with nearly 100 originating partners that operate under varying regulatory requirements.
He said the bank does not represent a change in Upstart’s primarily third-party funding strategy. However, it could allow the company to fund some of the approximately $1 billion of loans on its balance sheet more efficiently through lower-cost deposit funding and leverage.
Gu said operating-expense growth is expected to slow to low single-digit quarter-over-quarter growth in the second half of the year. He said Upstart expects to gain operating leverage as secured products improve, internal AI investments mature and the bank project moves toward its anticipated 2027 launch.
About Upstart (NASDAQ:UPST)Upstart Holdings, Inc operates a cloud-based lending marketplace that leverages artificial intelligence and machine learning to assess borrower creditworthiness. The company partners with banks and credit unions, providing its proprietary AI models and underwriting platform to facilitate consumer credit products. By focusing on non‐traditional data points—such as education, employment history and other real‐time indicators—Upstart seeks to improve approval rates and lower loss rates compared with conventional credit scoring methods.
Upstart's core offering centers on unsecured personal loans, which borrowers can use for purposes such as debt consolidation, home improvements or major purchases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Upstart Right Now?Before you consider Upstart, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstart wasn't on the list.
While Upstart currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
You are now leaving Barron's websiteBy clicking on the “Proceed” button below, you will be redirected to a third-party website owned and operated by Hong Kong Tiimoot Information Technology Co., Limited. (“HKT”), which is located in Hong Kong. That website operates independently from Barron's and Barron's does not control the website. The privacy practices of HKT are subject to its Privacy Statement, so please read it closely. We are not responsible for HKT's privacy or other data-related practices.
The companies said the deal will help meet surging demand for consumer broadband and converged services, accelerating Verizon's push to bring internet access to more homes and businesses across the nation.
